Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease

► We assess the cost-effectiveness of infliximab and adalimumab for chrohn's disease. ► A 5 year probabilistic Markov model used. ► Adalimumab costs $193,305 per quality adjusted life year (QALY)versus to usual care. ► Infliximab costs $451,165 per QALY compared to adalimumab. ► Infliximab and adalimumabmay be poor value for money for Chron's disease.